The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.
Published on August 20
Recent FDA rejections reinforce the high barriers protecting these companies. Their approved treatments enjoy market exclusivity that's incredibly difficult for competitors to challenge.
Rare disease treatments command premium prices with limited competition. These companies can maintain strong margins while serving critical patient needs that few others can address.
Having successfully navigated complex approval processes gives these firms a significant head start. New entrants face years of costly trials with uncertain outcomes.
Recent FDA rejections highlight the immense challenges in bringing new rare disease treatments to market. This creates a protective moat around companies that have already successfully navigated these rigorous approval processes, strengthening their competitive positions and market exclusivity.
These pharmaceutical companies focus on orphan drugs for rare diseases, benefiting from market exclusivity, strong pricing power, and reduced competition. The high barriers to entry in this space create durable revenue streams and protect established players from new entrants.
Each company was handpicked for having proven track records with approved therapies for rare conditions. Professional analysts selected these firms based on their ability to maintain market leadership and generate stable returns in the wake of competitor setbacks.
Market capitalisation breakdown for a basket focused on companies with orphan drug moats in rare disease.
RARE: $3.29B
FOLD: $2.61B
SRPT: $2.44B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+7
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+165.46%
On average, analysts expect assets in this group to grow 165.46% over the next year.
11 of 14 assets in this group are rated Buy by professional analysts.
